Opinion
Volume 16:04, 2024

Journal of Cancer Science and Therapy

ISSN: 1948-5956 Open Access

Epigenetic Modifications in Cancer: Mechanisms and Therapeutic Targets

Samuel King*

Department of Epidemiology, University of Ankara, Ankara, Türkiye

Introduction

Epigenetic modifications, which influence gene expression without altering the DNA sequence, have emerged as crucial factors in cancer development and progression. This article explores the mechanisms underlying epigenetic modifications in cancer, including DNA methylation, histone modification and non-coding RNA regulation. Additionally, it examines current therapeutic strategies targeting these epigenetic alterations and discusses future directions for research and treatment. Cancer is a complex disease characterized by uncontrolled cell growth and proliferation. While genetic mutations play a critical role in cancer, epigenetic modifications also significantly contribute to tumorigenesis. These modifications can alter gene expression patterns, contributing to the aberrant activation or silencing of genes involved in cancer. Understanding the mechanisms of epigenetic modifications and identifying potential therapeutic targets is essential for developing effective cancer treatments. DNA methylation involves the addition of a methyl group to the 5-position of cytosine residues within CpG dinucleotide. In normal cells, DNA methylation is crucial for gene silencing and maintaining genomic stability. In cancer, aberrant DNA methylation patterns are commonly observed. Hyper methylation of tumour suppressor gene promoters can lead to their silencing, while hypo methylation can activate oncogenes or cause chromosomal instability. For example, the promoter of the tumour suppressor gene p16INK4a is frequently hyper methylated in various cancers, contributing to loss of cell cycle control [1].

Histones, the protein components around which DNA is wrapped, are subject to various post-translational modifications, including acetylation, methylation, phosphorylation and ubiquitination. These modifications affect chromatin structure and gene expression. In cancer, abnormal histone modification patterns are observed. For instance, increased histone H3K27 trimethylation is associated with gene silencing in many cancers, while abnormal acetylation patterns can lead to the activation of oncogenes. The balance between activating and repressive histone marks is disrupted in cancer, contributing to the aberrant gene expression profiles observed in tumours. Non-coding RNAs are RNA molecules that do not encode proteins but play critical roles in regulating gene expression. Two major classes of ncRNAs involved in cancer are microRNAs and long non-coding RNAs. miRNAs regulate gene expression by binding to target mRNAs and inhibiting their translation or inducing their degradation. Aberrant expression of miRNAs can lead to the deregulation of cancer-related genes. Similarly, lncRNAs can modulate gene expression through various mechanisms, including chromatin remodelling and interaction with transcription factors. The deregulation of both miRNAs and lncRNAs is commonly observed in cancer and contributes to tumour progression [2].

Description

Several drugs targeting DNA methylation have been developed as cancer therapies. Gemcitabine and azacitidine are cytosine analogies that inhibit DNA methyltransferases, leading to the reactivation of silenced tumour suppressor genes. These drugs have shown efficacy in treating haematological malignancies such as Acute Myeloid Leukemia (AML) and myelodysplastic syndromes. However, their use in solid tumours is less well-established and on-going research aims to optimize their efficacy and minimize side effects. Histone deacetylase inhibitors, such as vorinostat and romidepsin, target the enzymes responsible for removing acetyl groups from histones, leading to an open chromatin structure and reactivation of silenced genes. These inhibitors have shown promise in treating lymphomas and multiple myeloma. Combination therapies involving HDAC inhibitors and other treatments are being explored to enhance their efficacy and overcome resistance. Beyond DNA methylation and histone modification, other epigenetic enzymes are being targeted for cancer therapy. For example, bromodomain and extra terminal protein inhibitors, such as JQ1, target proteins that recognize acetylated histones and regulate transcription. These inhibitors have demonstrated anti-tumour activity in preclinical models and early clinical trials. Additionally, small molecules targeting histone methyltransferases and demethylases are being developed to reverse aberrant histone methylation patterns in cancer cells [3].

Strategies targeting non-coding RNAs are also being explored. For example, synthetic miRNA mimics or inhibitors can be used to restore normal miRNA expression or block oncogenic miRNAs. Similarly, antisense oligonucleotides and RNA interference technologies are being developed to target deregulated lncRNAs. While these approaches hold promise, challenges remain in delivering these therapies effectively and specifically to cancer cells. One of the future directions in epigenetic cancer therapy is personalized treatment based on the specific epigenetic alterations present in individual tumours. Advances in epigenetic profiling technologies allow for the identification of unique epigenetic signatures associated with different cancer types and patient subgroups. Tailoring therapies to these signatures could enhance treatment efficacy and minimize adverse effects. Resistance to epigenetic therapies remains a significant challenge. Tumour cells can develop resistance mechanisms, such as the acquisition of secondary mutations or alterations in epigenetic pathways. Combining epigenetic therapies with other treatment modalities, such as targeted therapies or immunotherapies, may help overcome resistance and improve patient outcomes. Cancer cells exhibit epigenetic plasticity, allowing them to adapt to changing environments and treatment pressures. A better understanding of how cancer cells utilize epigenetic plasticity to evade therapy will be crucial for developing more effective and durable treatments [4,5].

Conclusion

Epigenetic modifications play a pivotal role in cancer development and progression by altering gene expression patterns. Advances in understanding the mechanisms of DNA methylation, histone modification and non-coding RNA regulation have led to the development of novel therapeutic strategies targeting these epigenetic alterations. While significant progress has been made, challenges remain in optimizing these therapies and overcoming resistance. Future research focusing on personalized treatments, understanding resistance mechanisms and exploring epigenetic plasticity will be essential for advancing cancer treatment and improving patient outcomes.

***Address for Correspondence:** Samuel King, Department of Epidemiology, University of Ankara, Ankara, Türkiye; E-mail: samuelking@gmail.com*

Received: 12 June, 2024, Manuscript No. jcst-24-148397; **Editor assigned:** 14 June, 2024, PreQC No. P-148397; **Reviewed:** 26 June, 2024, QC No. Q-148397; **Revised:** 01 July, 2024, Manuscript No. R-148397; **Published:** 08 July, 2024, DOI: 10.37421/1948-5956.2024.16.654

Acknowledgement

None.

Conflict of Interest

None.

References

1. Van Herpe, Filip and Eric Van Cutsem. "The role of cMET in gastric cancer-A review of the literature." *Cancers* 15 (2023): 1976.
2. Jie, Guang-Ling, Lun-Xi Peng, Mei-Mei Zheng and Hao Sun, et al. "Longitudinal plasma proteomics-derived biomarkers predict response to MET Inhibitors for MET-Dysregulated NSCLC." *Cancers* 15 (2023): 302.
3. Jørgensen, Jan Trøst and Jens Mollerup. "Companion diagnostics and predictive biomarkers for MET-targeted therapy in NSCLC." *Cancers* 14 (2022): 2150.
4. Dumitru, Claudia Alexandra, Eileen Brouwer, Tamina Stelzer and Salvatore Nocerino, et al. "Dynein light chain protein Tctex1: A novel prognostic marker and molecular mediator in glioblastoma." *Cancers* 13 (2021): 2624.
5. Sampl, Sandra, Sibylle Pramhas, Christian Stern and Matthias Preusser, et al. "Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade." *Trans Oncol* 5 (2012): 56-IN4.

How to cite this article: King, Samuel. “Epigenetic Modifications in Cancer: Mechanisms and Therapeutic Targets.” *J Cancer Sci Ther* 16 (2024): 654.